Genghis Lloyd-Harris

Genghis Lloyd-Harris is a prominent figure in the life sciences investment sector, currently serving as a Senior Advisor at Abingworth, a transatlantic life sciences investment firm. He previously held the position of Partner at Abingworth, where he specialized in the exits of venture investments through mergers and acquisitions and initial public offerings (IPOs) .12

Educational Background

• Medical Degree: University of Liverpool, UK
• PhD in Clinical Pharmacology: University of Melbourne, Australia
• MBA: Harvard Business School

Professional Experience

• Abingworth: Joined in 2004 from Credit Suisse First Boston (CSFB), where he was a Managing Director in the European Equity Research Group. At CSFB, he was recognized for his expertise in European biotechnology, ranking first in Institutional Investor surveys from 2001 to 2003.
• Healthcare Roles: Prior to his finance career, Genghis practiced as a pediatrician in Melbourne, Australia.

Board Positions

Genghis has held board roles in several notable companies, including:

• Avillion
• GenSight Biologics
• Healthcare Brands International
• Nouscom
• Novexel
• Solexa
• Synosia Therapeutics
• Syntaxin
• Wilson Therapeutics

Current Role

As a Senior Advisor, Genghis continues to influence the strategic direction of Abingworth and its portfolio companies. His extensive background in both healthcare and finance positions him as a key player in advancing innovative therapies in the life sciences sector .123